Inflammatory bowel disease, especially Crohn’s disease and ulcerative colitis, occupy a prominent place in the structure of gastrointestinal disorders, negatively affecting the quality of life of people of working age and is an important cause of loss of earning capacity.
The conventional treatment of inflammatory bowel disease, including anti-inflammatory therapy, antibodies to tumor necrosis factor-alpha, unfortunately, does not always allow to achieve the desired effect. According to modern research, cell therapy will become the next generation of medicines in the treatment of Crohn’s disease and ulcerative colitis.
In the 1st issue of the international medical journal «Gastroenterology and Hepatology: open access» (2014) scientific review article of CM Nasadyuk (Ukraine) «Stem cell therapy in the treatment of inflammatory bowel disease» was published («Stem Cell Therapy In The Treatment of Inflammatory Bowel Disease»).
The article summarizes preclinical and clinical experience of the application of different populations of stem cells in the treatment of inflammatory bowel disease. In the treatment of Crohn’s disease and ulcerative colitis both hematopoietic stem cells from the bone marrow, umbilical cord blood and peripheral blood are being investigated and in the world practice significant experience of the use of mesenchymal stem cells, also isolated from the bone marrow or umbilical cord blood and amniotic fluid or adipose tissue was accumulated.
Analysis of uptodate scientific literature suggests that cell therapy of inflammatory bowel disease involves two approaches:
1. Immunosuppression followed by hematopoietic stem cells transplantation;
2. Application of mesenchymal stem cells, possessing both immunosuppressive and regenerative effects.
Today more than 200 clinical studies on the therapeutic efficacy of mesenchymal stem cells are registered worldwide, of which more than 20 are devoted to the treatment of Crohn’s disease and ulcerative colitis. Cell therapy has been carried out in more than 1 500 patients with inflammatory bowel disease.
Cell therapy of Crohn’s disease and ulcerative colitis is primarily indicated for patients with resistancy to anticytokine therapy, as well as hormone-resistant and hormone-dependent forms of the disease. It was noted that the use of stem cells in Crohn’s disease and ulcerative colitis results in reduction of glucocorticoids dosage in the treatment of these patients.
Modern researchers have also obtained data on the efficacy of cell therapy in the treatment of celiac disease and other genetically determined diseases of the intestine.
Thus, the use of stem cells significantly expands the arsenal of therapeutic agents in the treatment of patients with inflammatory bowel disease and will increase the efficiency of treatment of this severe pathology, as well as the quality of life of patients.
We suggest reading the full article: http://medcraveonline.com/GHOA/GHOA-01-00006.php